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Abstract
The life cycle of human papillomaviruses (HPV) is tightly regulated by the differentiation state of 
mucosal and cutaneous keratinocytes. To counteract viral infection, constitutively expressed 
cellular factors, which are defined herein as restriction factors, directly mitigate viral gene 
expression and replication. In turn, some HPV gene products target these restriction factors and 
abrogate their anti-viral effects to establish efficient gene expression and replication programs. 
Ironically, in certain circumstances, this delicate counterbalance between viral gene products and 
restriction factors facilitates persistent infection by HPVs. This review serves to recapitulate the 
current knowledge of nuclear restriction factors that directly affect the HPV infectious cycle.
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1. Introduction
The human immune system consists of both adaptive and non-adaptive responses that 
function to restrict and clear viral pathogens. Adaptive immune responses are tailored 
specifically to individual pathogens, while non-adaptive immunity (comprised of “intrinsic” 
and “innate” responses) provides an initial barrier to invading pathogens (Iwasaki and 
Medzhitov, 2015). All three types of immunity (intrinsic, innate, and adaptive) contribute to 
the restriction and clearance of viral pathogens in humans. The innate immune response is 
not specific for individual pathogens but is rapidly induced when an invading pathogen is 
detected. Restriction factors that mediate intrinsic immune responses to pathogens are pre-
existing in cells (though they may also be induced) and function to quickly shut down viral 
infections (Yan and Chen, 2012).
Intrinsic anti-viral immunity is mediated through cellular restriction factors that directly, and 
immediately, inhibit infection at various steps in the viral life cycle. Viral infection can be 
restricted upon cell entry, trafficking through the endosome and trans-golgi network, 
uncoating, or nuclear entry. Restriction factors can also inhibit transcription and translation 
of viral genes, replication of the viral genome, and assembly/release of viral particles). As 
described below, the HPV infectious cycle has three main phases: viral entry and 
establishment; persistent infection in undifferentiated cells; and, productive infection in 
differentiated cells. Host factors could restrict any of these stages of infection to prevent, or 
reduce, production of progeny virions. However, one characteristic of intrinsic restriction 
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factors, is that viruses have almost always evolved strategies to evade or counteract the anti-
viral function (Yan and Chen, 2012).
Other chapters in this Special Issue will focus on related topics of innate immunity to HPV 
(Westrich et al., 2016), entry and trafficking of papillomaviruses (DiGiuseppe et al., 2016a), 
and interferon and NFκB induced pathways (Hong and Laimins, 2016). In this article, we 
will focus on intrinsic nuclear factors that directly restrict papillomavirus replication and 
transcription.
2. HPV Infectious Cycle
Papillomaviridae are a family of non-enveloped, DNA viruses that infect a wide spectrum of 
vertebrate hosts and are trophic for human mucosal and cutaneous keratinocytes. HPVs are 
associated with a multitude of human pathologies, including benign and malignant tumors 
(Cubie, 2013). Additionally, a subset of viruses within the alpha genus are deemed “high-
risk” HPVs; they are the etiological agents of nearly all cases of human cervical cancer and 
are highly associated with other cancers such as oropharyngeal carcinoma (Gillison et al., 
2000). HPVs have a small, dsDNA genome that is approximately 8,000 base pairs in length. 
All papillomavirus genomes have four core viral open reading frames (ORFs): E1, the viral 
helicase important for viral genome replication (Bergvall et al., 2013); E2, the helicase 
loader and major transcriptional regulatory protein (McBride, 2013); E8^E2, a 
transcriptional repressor (Dreer et al., 2016b); and the major and minor capsid proteins, L1 
and L2 (Buck et al., 2013; Wang and Roden, 2013). Moreover, many PVs encode additional 
ORFs: E4, E5, E6, E7 and E10 (DiMaio and Petti, 2013; Doorbar, 2013; Roman and 
Munger, 2013; Van Doorslaer and McBride, 2016; Van Doorslaer et al., 2013; Vande Pol and 
Klingelhutz, 2013). These accessory genes encode products that are involved with cell cycle 
deregulation, immune evasion and recruitment of host factors for replication. Figure 1 
demonstrates a prototypical HPV genome from the alpha-PV genus, which encodes many of 
these gene products.
The HPV life cycle is entirely coincident with, and codependent on, the differentiation 
process of the host epithelium. The virus infects, and establishes a persistent infection in, the 
basal cells of the epithelium that it accesses through micro-abrasions. As the infected cells 
progress through differentiation, viral DNA is amplified, late genes are expressed, and the 
virus assembles in the most superficial layers of the epithelium (See Figure 2).
The HPV capsid consists of the two viral proteins, L1 and L2, which are both necessary for 
infection (Holmgren et al., 2005; Richards et al., 2006). L1 is the major structural capsid 
protein, and initially interacts with heparin sulfate proteoglycans (HSPGs) on the cell 
surface (Giroglou et al., 2001; Joyce et al., 1999) and extracellular matrix of the basement 
membrane of the epithelium (Kines et al., 2009; Selinka et al., 2007). This interaction 
induces a conformational shift within the capsid that exposes an epitope on the minor capsid 
protein, L2 (Richards et al., 2006). The virus binds a secondary (as yet uncharacterized) 
receptor, enters the cell by endocytosis and is trafficked through the endosomal pathways 
into the trans-golgi network. Many viruses protect their genomes in capsids until viral DNA 
is delivered to the nucleus. However, HPV is uncoated as it traffics through the endosomal 
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compartment, and L2 is the only capsid protein that remains associated with the viral DNA 
as it moves to the Golgi network (Day et al., 2013). Finally, the virus arrives at the nuclear 
membrane, where it requires cell division to occur (resulting in nuclear membrane 
breakdown) before it gains access to the nucleus (Aydin et al., 2014; Pyeon et al., 2009). 
Recent evidence shows that the L2-genome complex is delivered to the nucleus in a 
membranous vesicle that traffics along microtubules and binds host chromosomes, 
remaining there until the end of mitosis (DiGiuseppe et al., 2016b). The viral genome is 
protected within these vesicles until about four hours after the completion of mitosis.
Early in infection (presumably after the completion of mitosis), the L2:DNA complex 
becomes localized adjacent to nuclear structures known as Nuclear Domain 10 (ND10) 
bodies (Day et al., 2004). The L2 protein reorganizes proteins within the ND10 structure, 
making it conducive as a site for the establishment of transcription and replication of the 
viral DNA (Becker et al., 2003; Florin et al., 2002). Early viral transcripts are synthesized 
shortly after infection (Ozbun, 2002), and this is initiated by cellular factors since the HPV 
virion does not contain any transcriptional regulatory proteins. These early transcripts 
encode the E1 and E2 viral replication proteins, which are required to initiate viral DNA 
replication. The HPV genome then undergoes a minor burst of viral DNA amplification (the 
first of the three stages of viral DNA replication). E1 and E2 cooperatively bind to the 
replication origin, to unwind the strands of the viral genome (McBride, 2008). This process 
promotes initiation of replication at the origin, which proceeds using cellular factors to 
synthesize viral DNA. This unscheduled DNA synthesis engages the cellular DNA damage 
response (DDR) (McKinney and McBride, 2016; Reinson et al., 2013), which likely alerts 
cell restriction pathways. In fact, expression of the E1 protein is sufficient to induce the 
ATM/ATR DNA damage response pathways (Fradet-Turcotte et al., 2011; Reinson et al., 
2013; Sakakibara et al., 2011).
The E2 protein also serves as the master regulator of viral transcription (McBride, 2013). 
The binding of E2 to E2 binding sites (E2BS) located in the Upstream Regulatory Region 
(URR) of the viral genome can positively or negatively regulate the transcriptional activity 
of the early promoter, depending on the levels of E2 and the ratio of E2 isoforms that 
function as competitors of E2BS (Ammermann et al., 2008; Fertey et al., 2010). These 
isoforms are known by various names, but most often E8^E2 (this issue (Dreer et al., 
2016b)). E8^E2 represses early viral transcription as well as viral DNA replication 
(Ammermann et al., 2008) by interacting with the cellular NCoR/SMRT corepressor 
complexes (Dreer et al., 2016a). Thus, the viral E8^E2 protein restricts the viral life cycle, 
which helps avoid immune detection and promotes persistent/latent infection.
During the persistent, maintenance phase of the viral life cycle, the virus goes to great 
lengths to limit DDR signaling by keeping levels of viral DNA at low levels, and limiting the 
presence of the replication proteins in the nucleus. This is carried out shuttling the E1 
protein to the cytoplasm when it is not required for replication (Deng et al., 2004). There is 
also evidence that the E1 protein might not be necessary for this mode of replication (Egawa 
et al., 2012; Kim and Lambert, 2002). Cellular factors that can further inhibit viral 
replication (and will be discussed in detail below) are p53 and cellular miRNAs that target 
the E1 and E2 coding regions.
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In addition to its role in initiation of DNA replication, the E2 protein is responsible for 
ensuring that newly replicated viral genomes are efficiently transferred from parent to 
daughter cells as they undergo mitosis (Bastien and McBride, 2000; Ilves et al., 1999; 
Skiadopoulos and McBride, 1998). This process is essential for stable genome maintenance 
in infected, undifferentiated basal keratinocytes and is critical to the long-lived, persistent 
nature of HPV infections.
The E6 and E7 oncoproteins of the high-risk alpha-PVs contribute to many different 
processes in the early stages of viral life cycle (Roman and Munger, 2013; Vande Pol and 
Klingelhutz, 2013)) but, most notably, they disable major cell cycle checkpoints to provide 
the virus with an environment conducive to replication in stratified epithelial tissue. E6 and 
E7 also interfere with interferon and NFκB signaling pathways (Beglin et al., 2009; Chang 
and Laimins, 2000; Tummers and Burg, 2015). There are many similarities between tumor 
suppressor pathways and immune signaling pathways and it has been proposed that the 
primary reason that oncogenic viruses target these pathways is, in fact, for immune evasion 
(Moore and Chang, 2010)
Following loss of keratinocyte attachment to the basement membrane during the process of 
differentiation, HPVs switch from a low-copy, maintenance mode of viral replication to a 
productive replication phase. The mode of replication is again dependent on E1 and E2 
(Egawa et al., 2012; Ozbun and Meyers, 1998), and amplifies viral DNA to high copy 
number. E1 and E7 independently promote a DNA damage response (DDR) that recruits 
factors that the virus can hijack to replicate its DNA outwith S-phase (Gautam and Moody, 
2016; McKinney et al., 2015). During this phase, there is sustained synthesis of intermediate 
(E1, E2 and E4) and late (L1 and L2) transcripts. The E4 protein is the most abundant 
protein present in the upper layers of infected epithelium and interacts with keratins to 
reorganize the dense, rigid network of dead or dying cells in the stratum corneum, to 
facilitate viral transmission (Doorbar, 2013). Production of high levels of capsid proteins L1 
and L2 results in encapsidation of viral DNA within the nucleus, concomitant with assembly 
of viral capsids.
3. Papillomaviruses and the intrinsic immune response
The epithelium itself provides the first line of defense against viral pathogens; this physical 
barrier is further protected by a mucus layer containing anti-microbial peptides or defensins 
(Buck et al., 2006). But occasionally the virus breaches this barrier through microabrasions 
(Roberts et al., 2007), which allows it access to the progenitor basal cells. The ensuing 
persistent, differentiation-dependent life cycle is also a strategy to escape from immune 
detection, as high level gene expression, and cytopathic effects, occur only in short-lived, 
terminally differentiated cells (Stanley, 2012). HPVs enter cells via endocytic pathways 
(Hindmarsh and Laimins, 2007; Popa et al., 2012; Smith et al., 2007); however, HPVs do not 
strongly activate endosomal immune sensors during entry (Tummers and Burg, 2015). In 
agreement, typical antiviral response factors (IFN-β, TNF-α, IFI16, IL-6 and RIG-I) are not 
induced during the initial stages of infection by canine papillomavirus (Luff et al., 2013). 
The viral capsid is not disassembled until it reaches the late endosome and the viral genome 
remains in complex with host histones and the minor capsid protein, L2 as it escapes the 
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endosomal compartment (Bergant Marusic et al., 2012; Kamper et al., 2006). Furthermore, 
the L2-minichromosome complex remains in membrane vesicles that track to host 
chromosomes when the nuclear membrane breaks down during cell division (DiGiuseppe et 
al., 2016b), further protecting it from immune recognition.
Upon entry into the nucleus, the virus encounters additional intrinsic defenses that restrict 
viral replication and transcription, and this will be the focus of this review. The viral 
genome-L2 complex is observed localized to ND10 bodies early after infection (Day et al., 
2004), presumably after the cell has progressed through mitosis (Pyeon et al., 2009). It has 
been shown that the viral DNA initially localizes with mitotic chromatin (Cerqueira and 
Schelhaas, 2015; DiGiuseppe et al., 2016b), but it is unclear how the viral DNA is trafficked 
from mitotic chromatin to ND10. ND10 bodies are thought to play a role in anti-viral 
defense and many DNA viruses localize here early in infection, but disrupt the bodies or 
some of their components (Maul, 1998). The PML protein is necessary for both BPV1-
pseudovirus and wart-derived BPV1 virions to efficiently transcribe their packaged genomes 
upon infection (Day et al., 2004). HPV18 infection of primary human keratinocytes is also 
slightly impaired when PML is reduced by siRNA treatment (Stepp et al., 2013). Therefore, 
while ND10 bodies are considered to be anti-viral, they provide a favorable nuclear location 
for the initial stages of HPV infection. Once the genome has arrived at ND10, viral 
transcription is required to express the E1 and E2 proteins in order to replicate the viral 
DNA. This restricted gene amplification likely involves the DDR machinery, and many DDR 
factors localize, at least transiently, to ND10 bodies (Barr et al., 2003; Lombard and 
Guarente, 2000; Xue et al., 2003; Zhong et al., 1999). Therefore, this site might be 
advantageous for the virus to initiate the early stages of viral replication and transcription. 
Conversely, the ND10 bodies contain repressive factors, such as Sp100 and Daxx; however, 
viruses have evolved various ways to interfere with their functions.
During the maintenance phase of infection, the viral genome replicates in synchrony with 
the host genome and is likely tolerated by the cell better than the multiple rounds of 
unscheduled DNA amplification that occur at the early and late stages of infection. However, 
the virus is still under immunosurveillance, as immunosuppression or immunodeficiency 
results in a great increase in productive infection (Leiding and Holland, 2012). Viral proteins 
expressed at this stage (E5, E6, and E7) counteract many pathways such as the interferon 
response, DNA damage response and antigen presentation (DiMaio and Petti, 2013; Roman 
and Munger, 2013; Vande Pol and Klingelhutz, 2013) and the virus-host interaction reaches 
a balance that allows the virus to be tolerated at low levels.
In the last phase of infection, viral DNA replication and transcription are induced to high 
levels by keratinocyte differentiation (Bedell et al., 1991). There is less immune surveillance 
in these terminally differentiated cells, which permits the persistently infected cells in the 
lower layers to coexist in a lesion with overlying virus producing cells (Stanley and Sterling, 
2014). However, cellular restriction factors can still modulate viral activity in the 
differentiated epithelium, suggesting that the viral-host arms race continues in the latest 
stages of viral infection (Stanley and Sterling, 2014).
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4. Host Factors that restrict transcription and Replication of 
Papillomaviruses
In this section we describe specific host factors that restrict HPV transcription and 
replication. We also describe how factors that are restriction factors for other viruses, 
modulate the HPV life cycle.
4.1 ND10 factor: PML
ND10 bodies (also known as PML nuclear bodies) are spherical, sub-nuclear structures that 
are integral to many different functions within the cell (Lallemand-Breitenbach and de The, 
2010). As described above, HPV genomes traffic here during the early stages of infection. 
The PML protein is the critical nucleating factor, or scaffolding protein, upon which the 
ND10 body is organized (Ishov et al., 1999). Interaction with Ubc9, a SUMO-E2 ligase, 
deposits SUMO moieties on PML (Duprez et al., 1999), and promotes oligomerization of 
PML dimers, ultimately resulting in the assembly of the ND10 scaffold (Shen et al., 2006). 
Proteins interact with ND10 through one of two primary mechanisms: either direct protein-
protein interactions with the PML backbone, or, more commonly, through SUMO-mediated 
interactions (Van Damme et al., 2010). The ND10 structure is highly dynamic, and 
undergoes changes in composition depending on the needs of the cell and the stage of the 
cell cycle. During interphase, ND10 bodies are observed as punctate nuclear foci, and many 
ND10 interacting proteins localize here. However, as cells progress towards mitosis, the 
punctate nuclear staining typical of PML is lost and the PML protein is observed in globular 
structures, clearly distinct from mitotic chromosomes and without SUMO (Everett et al., 
1999b).
DNA viruses both interact with and manipulate these structures (Maul, 1998). Upon entering 
the nucleus many DNA viruses initiate their transcription and replication programs at, or 
adjacent to, ND10 bodies. At the same time, viral capsid, tegument or immediate-early 
proteins simultaneously reorganize or degrade ND10 associated factors (Scherer and 
Stamminger, 2016). The presence of the PML protein itself plays a positive role in initial 
papillomavirus infection (Day et al., 2004; Stepp et al., 2013). So, while PML does not 
suppress HPV infection, the ND10 bodies are an important location for the virus and contain 
other factors that restrict viral transcription and replication. PML is a depot for transcription 
factors, replication factors, and DNA damage repair proteins, and so association of the virus 
with PML may be a strategy for the virus to focus cellular and viral factors adjacent to 
replicating viral DNA.
4.2 ND10 factor: Daxx
Daxx is a component of ND10 bodies and contributes to its role in intrinsic immunity 
(Everett et al., 1999a). Daxx serves as a chaperone that assists in formation of nucleosomes 
and promotes specific deposition of H3.3 onto histone-free DNA (Lewis et al., 2010). Daxx 
associates with the chromatin-remodeling component, ATRX (α-thalassemia X-linked 
mental retardation protein) at ND10 (Xue et al., 2003), recruiting histone deacetylases, 
mobilizing ATRX to heterochromatin, and facilitating nucleosome deposition (Lewis et al., 
2010; Schreiner and Wodrich, 2013). Daxx is also implicated in the repression of viral 
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transcription for many DNA viruses (such as HCMV and adenovirus) and, like PML, is 
antagonized by viral proteins from several different virus types during the early stages of 
infection (Scherer and Stamminger, 2016). During HCMV infection, Daxx inhibits viral IE 
gene expression and is targeted for proteasomal degradation by the viral tegument protein 
pp71 (Saffert and Kalejta, 2006). Similar processes have been observed in HSV-1 infection, 
where ICP0 antagonizes the anti-viral effects of the Daxx-ATRX complex (Lukashchuk and 
Everett, 2010), and for adenovirus where E1B-55K protein inhibits Daxx and targets ATRX 
for proteasomal degradation (Schreiner et al., 2013).
However, contrary to its role in the life cycle of other DNA viruses, Daxx has a positive role 
in HPV transcription. In U2OS cells in which Daxx has been downregulated, both HPV 
early transcription and viral DNA replication are reduced (Kivipold et al., 2015). Similarly, 
Daxx depletion in primary human keratinocytes modestly impairs early viral gene 
expression and initial amplification of the HPV genome (Stepp et al., 2013). Expression of 
the minor capsid protein, L2, strongly recruits nuclear Daxx to ND10 bodies (Florin et al., 
2002), while displacing Sp100 (Florin et al., 2002; Stepp, 2015) and L2 interacts with Daxx, 
even in the absence of PML (Becker et al., 2003). Thus, while L2 appears to behave like 
other viral factors that antagonize ND10 associated restriction factors, it seems to recruit 
Daxx. Further studies are required to determine the mechanistic role of L2 on Daxx protein 
function, and to determine whether ND10 localization of L2 is necessary for the early (upon 
infection), or late (during packaging) stages of infection.
4.3 ND10 factor: Sp100
There are four distinct isoforms of the Sp100 protein (Sp100A, Sp100B, Sp100C, and Sp100 
HMG), some of which constitutively associate with the ND10 bodies (Negorev et al., 2006). 
Each isoform contains a dimerization domain and a domain that mediates binding of Sp100 
to HP1 (Sternsdorf et al., 1999). Sp100B, −C, and −HMG have an additional SAND (Sp100, 
AIRE-1, NucP41/45, and DEAF-1) DNA binding domain that mediates direct binding to 
unmethylated CpG sequences (Bottomley et al., 2001; Isaac et al., 2006). Additionally, 
Sp100C and HMG isoforms contain either additional HMG box DNA binding motifs 
(Sp100HMG), or bromodomain and plant homeodomain (PHD) finger chromatin interaction 
motifs (Sp100C). The presence of these chromatin association domains and DNA binding 
motifs in the Sp100 isoforms strongly implicate these proteins in the regulation of gene 
expression. Sp100 has been linked with cellular transcriptional regulation due to its 
colocalization and interaction with nuclear regulatory factors like heterochromatin protein-1 
alpha (HP-1α) (Seeler et al., 1998), and transcriptional intermediary factor (TIF) (Seeler et 
al., 2001), as well as coregulation of several cellular genes (Seeler et al., 1998 ; Wasylyk et 
al., 2002; Zong et al., 2000). Yet, surprisingly little is known about the overarching role of 
Sp100 in cellular gene regulation.
In contrast, well-characterized studies of adenoviruses and herpesviruses underscore the 
importance of Sp100 in the context of viral infection and implicates these proteins as 
potential effectors in the response to viral infection. Early studies indicated that Sp100, like 
other core ND10 proteins was a repressor of viral infection. However, more detailed 
analyses indicate that the shortest and most abundant isoform, Sp100A activates 
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transcription, whereas the longer isoforms repress transcription (Berscheminski et al., 2014; 
Negorev et al., 2006; Newhart et al., 2013; Wilcox et al., 2005). Sp100 proteins are 
upregulated by interferon and viral proteins alter, displace or degrade Sp100 (Guldner et al., 
1992; Lavau et al., 1995). In cells infected with adenovirus, the immediate early proteins 
expressed from the E1 and E4 ORFs mediate a dramatic morphological change in the ND10 
bodies, expelling the repressive Sp100 isoforms −B, −C, and −HMG before forming 
replication factories within PML-containing tracks; however, the activating isoform Sp100A 
is retained and hijacked by the virus (Berscheminski et al., 2014; Doucas et al., 1996). 
Adenovirus infection abrogates binding of Sp100A to HP-1β, which results in 
decondensation of chromatin and enhanced viral gene expression (Berscheminski et al., 
2014).
HSV-1 DNA also localizes adjacent to ND10 structures (Maul et al., 1996) and it is thought 
that viral transcription and replication initiate here. Nucleoplasmic Sp100B, −C, and −HMG 
isoforms repress early HSV transcription, outside PML bodies, while Sp100A accumulates 
at ND10 and does not significantly impact HSV-1 ICP0 or ICP4 production (Negorev et al., 
2006). In order to mitigate the anti-viral functions of ND10 bodies, HSV-1 ICP0 targets 
Sp100 and PML for proteasomal degradation (Gu and Roizman, 2003).
Incoming HPV18 genomes (introduced by transfection, or by quasivirus infection) are 
similarly subjected to Sp100-mediated transcriptional repression with a concomitant 
inhibition of initial amplification of viral DNA (Stepp et al., 2013). These effects on initial 
infection also abrogate the establishment of persistent HPV18 infection, as measured by a 
quantitative colony forming assay. However, Sp100 has either minimal (Habiger et al., 
2016), or no (Stepp et al., 2013) significant effects on viral transcription or replication in 
cells maintaining HPV31 or HPV18 genomes. During the late stages of HPV31 infection, 
PML and Sp100 localize next to replication foci and, in some instances, infiltrate the 
replication factories (Stepp, 2015). Additionally, Sp100 represses late viral transcription and 
vegetative viral DNA amplification (Stamos and McBride, unpublished; Stepp, 2015). These 
results suggest that Sp100 represses transcription and DNA amplification during both early 
and late stages of the HPV life cycle.
Similar to other viruses, Sp100 B, C, and HMG isoforms repress HPV transcription, while 
Sp100A has no effect (Habiger et al., 2016; Stepp, 2015). Notably, Sp100A and Sp100C 
isoforms are specifically downregulated at the mRNA level in a variety of cell lines 
harboring HPV16 and HPV31 genomes (Habiger et al., 2016). All Sp100 isoforms are 
induced by interferon, but E6 downregulates constitutive IFN-κ expression in keratinocytes 
by hypermethylation of its promoter (Habiger et al., 2016; Reiser et al., 2011; Rincon-
Orozco et al., 2009). Thus, E6 may inhibit IFN-κ expression to downregulate the abundance 
of the Sp100 isoforms to subvert specifically innate immune functions mediated by these 
proteins. Therefore, the Sp100 family of proteins are important restriction factors for HPV.
4.4 p53, FANCD2 and the DNA Damage Response
The “high risk” HPV E6 and E7 proteins are considered oncogenes, and manipulate many 
steps in DDR and cell cycle regulatory pathways. While this promotes an environment 
conducive to viral DNA replication (and inadvertently promotes oncogenesis), it has been 
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proposed that the primary reason that these pathways are targeted is to disable anti-viral 
immune surveillance pathways (Moore and Chang, 2010).
Oncogenic HPV infection induces DNA damage signaling and p53 induction, which must be 
tempered to allow persistent replication of the viral genome. The viral E7 protein promotes 
cell cycle progression by inactivating pRb and p21, and deregulating E2F (Roman and 
Munger, 2013) to provide an environment conducive to viral DNA replication. However, the 
constant drive to promote proliferation causes nucleotide deficiency and promotes 
replication stress and genomic instability (Bester et al., 2011). This results in activation of 
p53, which should induce growth arrest, but E6 binds and degrades p53 to allow continued 
replication of viral DNA (Vande Pol and Klingelhutz, 2013). This ability of E6 to inactivate 
p53 is essential for persistent DNA replication (Flores et al., 2000; Park and Androphy, 
2002; Thomas et al., 1999) and HPV genomes mutated in E6 can only replicate in cells in 
which p53 has been inactivated (Brimer and Vande Pol, 2014; Lorenz et al., 2013).
Although DNA damage signaling can be detrimental to persistent HPV infection, it is 
beneficial for the productive phase of replication. Therefore, HPVs must inactivate some 
components of the DDR that can restrict the viral infectious cycle, but they also take 
advantage of other facets that are conducive for viral replication. The E1 and E2 proteins are 
induced to high levels in differentiating cells (Klumpp and Laimins, 1999) to amplify viral 
DNA. Both E1 and E7 activate the DNA damage response in these cells and this is required 
for genome amplification (Fradet-Turcotte et al., 2011; Gauson et al., 2015; Moody and 
Laimins, 2009; Reinson et al., 2013; Sakakibara et al., 2011). It is thought that engagement 
of the DDR machinery results in an influx of DNA damage and repair factors to replication 
foci to facilitate replication in differentiated cells (Gautam and Moody, 2016; Sakakibara et 
al., 2013).
Inactivation of p53 by E6 is also necessary for vegetative amplification of viral DNA. 
Viruses that cannot disarm p53 are also unable to amplify viral DNA in differentiated cells 
(Kho et al., 2013; Wang et al., 2009). Although much of the p53-mediated inhibition of HPV 
replication can be attributed to its role in checkpoint control, p53 can also directly inhibit 
viral DNA synthesis (Akgul et al., 2003; Ilves et al., 2003; Lepik et al., 1998). This 
inhibition can be mediated through direct interaction of p53 with the E2 protein (Brown et 
al., 2008; Massimi et al., 1999), which results in direct inhibition of viral DNA replication. 
Thus, p53 can be classified as a factor that restricts the viral life cycle.
The Fanconi anemia (FA) DNA repair pathway contains 15 genes involved in the error-free 
repair of intra-strand DNA cross-links and double stranded breaks. Individuals with a defect 
in any one of these genes are highly susceptible to HPV infection and have increased 
incidence of cancer development. These individuals are extremely vulnerable to squamous 
cell carcinomas in sites susceptible to HPV associated cancers, yet many of the resulting 
cancers are HPV negative (Park et al., 2016; van Zeeburg et al., 2008). E7 activates the FA 
pathway, and induces increased genetic instability in cells defective in the FA pathway 
(Spardy et al., 2007). The resulting genetic instability can render the FA-deficient cells no 
longer dependent on E7 (Park et al., 2016). Furthermore, in FA-deficient cells, productive 
HPV genome replication in differentiated cells is significantly higher, suggesting that the 
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functional FA pathway restricts the HPV life cycle (Hoskins et al., 2012). The details of this 
restriction have yet to be elucidated, but there is precedent that other viruses manipulate the 
FA pathway for replication. For example FA-mediated suppression of NHEJ promotes 
productive HSV-1 infection (Karttunen et al., 2014). More research is required to determine 
how the FA pathway suppresses HPV productive replication.
4.5 IFIT1 (p56)
Type I interferon (IFN) treatment of HPV infected cells causes the rapid loss of 
extrachromosomal HPV genomes (Chang et al., 2002; Herdman et al., 2006; Lace et al., 
2015; Turek et al., 1982). This is, at least in part, due to induction of the protein p56 (also 
known as IFIT1 or ISG56) (Saikia et al., 2010; Terenzi et al., 2008). The IFIT1 family of 
proteins are encoded by a group of interferon-stimulated genes (ISG) that are induced by 
viral infection (Fensterl and Sen, 2011). They share common structural elements called 
multiple tetratricopeptide motifs that mediate protein-protein interactions with effector 
proteins resulting in inhibition of many viral and cellular processes (Fensterl and Sen, 2011). 
The N-terminal region of IFIT1 binds directly to the C-terminal region of HPV18 E1 
(Terenzi et al., 2008). This interaction inhibits E1’s sequence-specific binding to the viral 
replication origin and blocks E1’s helicase function, thus inhibiting replication of HPV DNA 
(Saikia et al., 2010; Terenzi et al., 2008). Additionally, IFIT1 substantially inhibits the 
interaction of E1 with E2 (Saikia et al., 2010). Combined, these actions by IFIT1 act to 
inhibit significantly replication of the HPV genome.
4.6 IFI16
Many restriction factors sense, and respond to, incoming or foreign DNA. Most of these 
sensors are located in the cytosol, but more recently a nuclear DNA sensing factor, IFI16, 
has been described (Dempsey and Bowie, 2015). IFI16 is a member of the PHYIN family of 
proteins, and it recognizes invading DNA (and distinguishes from host DNA) in a length-
dependent, sequence-independent manner (Morrone et al., 2014). IFI16 binds to foreign 
DNA in a cooperative manner, and the resulting oligomeric, filamentous complexes recruit 
STING. This induces the expression of IFN-β in a TBK-1 dependent manner (Unterholzner 
et al., 2010). IFI16s requirement for a minimal sequence length of naked DNA ensures that 
host DNA exposed in the linker region between nucleosomes, or in transcription bubbles, are 
not recognized (Morrone et al., 2014).
IFI16 is a restriction factor for several other DNA viruses, including HSV-1 and HCMV 
(Gariano et al., 2012; Orzalli et al., 2013), and it induces anti-viral inflammasome activity 
against KSHV and EBV (Ansari et al., 2013; Roy et al., 2016). However, while IFI16 
restricts incoming HSV-1 DNA, it does not restrict SV40 DNA packaged in nucleosomes 
and delivered to the nucleus by transfection (Orzalli et al., 2013).
IFI16 is constitutively expressed in keratinocytes (Gariglio et al., 2002). Downregulation of 
IFI16 greatly increases HPV18 genome amplification in differentiated keratinocytes (Lo 
Cigno et al., 2015) and overexpression of IFI16 restricts both HPV18 replication and 
transcription in U2OS cells. This is mediated by modification of the chromatin state of the 
viral genome (Lo Cigno et al., 2015). IFI16 induces an increase of repressive 
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heterochromatic marks and a decrease in activating euchromatic marks on both the early and 
late promoters (Lo Cigno et al., 2015). (Lo Cigno et al., 2015). Interestingly, IFI16 is also 
able to reduce transcription from integrated genomes, possibly involving the Sp1 binding 
site in the LCR (Lo Cigno et al., 2015).(De Andrea et al., 2015)
It is not known how exactly IFI16 mediates this change in chromatin state in HPV; in its 
epigenetic-based restriction of HCMV, it is speculated that IFI16 binding to the viral genome 
induces a conformational change that promotes the recruitment of histone modification 
enzymes (Orzalli et al., 2013). These epigenetic modifications function to considerably 
reduce replication and viral transcription by making the viral genome less accessible to 
transcription and replication factors. However, the antiviral effect of IFI16 observed in HPV 
positive cells is independent of its role as a sensor of foreign DNA or activation of 
interferon.
4.7 APOBEC
An important host restriction factor, best studied in the context of HIV infection, is the 
APOBEC family of nucleic acid editing factors. APOBECs convert cytidines into uridine in 
RNA, but there is also evidence that certain APOBECs can induce mutations in genomic 
DNA (Shinohara et al., 2012). In fact, APOBEC proteins are upregulated in many cancers 
and the resulting APOBEC generated mutagenesis is widespread (Roberts et al., 2013). 
APOBEC3A and 3B are upregulated in HPV-associated cancers and this seems to be 
mediated by E7 functions (Warren et al., 2015a). Most HPV-related studies have focused on 
the ability of some members of the APOBEC family to edit HPV genomes in cancer cells, 
but APOBEC’s role as an intrinsic restriction factor of HPV infection remains less clear.
APOBECs edit single stranded DNA, so any action on HPV genomes must occur during 
viral transcription or replication. APOBEC editing has been detected in a small proportion 
of HPV containing lesions; genomes derived from some HPV1 infected cutaneous warts and 
HPV16 associated pre-malignant lesions show mutations consistent with APOBEC editing 
(Vartanian et al., 2008). Additionally, interferon treatment of W12 cells (cervical neoplasia 
derived cells containing extrachromosomal HPV16 genomes) induces endogenous APOBEC 
enzymes and results in mutation of viral DNA (Wang et al., 2014). Quasiviruses and 
pseudoviruses packaged in the presence of exogenous overexpressed hA3A show decreased 
early transcription (Ahasan et al., 2015; Warren et al., 2015b) and there is some evidence 
that this might interfere with packaging through interaction with the L1 protein (Ahasan et 
al., 2015). However, the precise role of APOBECs in the productive HPV infectious cycle is 
still not clear. HPVs are genetically very stable, and evolve at a very slow rate (Rector et al., 
2007), indicating that putative APOBEC-induced mutations are very rarely, if ever, fixed. 
However, alpha-HPVs, which mostly infect the anogenital mucosa, are relatively depleted in 
TC dinucleotides, the preferred target of APOBEC. This led Warren et al. to propose that, 
over a very long evolutionary period, alpha-HPVs have evolved to escape APOBEC editing 
(Warren et al., 2015a). Clearly, further studies are required to assess whether the APOBEC 
proteins restrict the HPV life cycle in natural infection.
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4.8 miRNA
Micro RNAs are small, non-coding regulatory RNAs that serve to bind to mRNA and silence 
gene expression. The opportunity to silence viral gene expression in a sequence specific 
manner, at the mRNA level, represents a powerful tool that host cells use as restriction 
factors against viral pathogens. Host miRNAs restrict many aspects of DNA virus (HBV, 
HCMV, and HSV-1) life cycles (Russo and Potenza, 2011).
HPV regulates the expression of many cellular miRNAs (Zheng and Wang, 2011). Of these, 
only a few are known to directly affect the viral infectious cycle. However, miR-145, has a 
pronounced, differentiation-dependent decrease in abundance in HPV31 infected cells, 
apparently mediated by E7 (Gunasekharan and Laimins, 2013; Gunasekharan et al., 2016). It 
is hypothesized that a sequence in the E1 open reading frame (ORF) is the primary target of 
miR-145, but there is also limited binding to the E2 ORF (Gunasekharan and Laimins, 
2013). Overexpression of miR-145 results in sharply reduced genome amplification and 
results in diminished late viral transcription, indicating an inhibitory role in the viral life 
cycle (Gunasekharan and Laimins, 2013). It is speculated that HPV relies on the inhibitory 
effects of miR-145 early in the life cycle to keep the copy number low during low level 
maintenance replication in undifferentiated cells (Gunasekharan and Laimins, 2013). Other 
viruses, such as KSHV and HSV-1, rely on virally-encoded miRNAs to maintain a latent 
state (Lu et al., 2010; Umbach et al., 2008). However, HPV does not express its own 
miRNAs (Cai et al., 2006) and thus must rely on manipulating or overcoming the host cells’ 
miRNA to maintain immune evasion.
4.9 C/EBPβ
CCAAT/enhancer binding proteins (C/EBPs) play a role in the regulation of differentiation 
program of many different cell types. C/EBPβ is present in the nuclei of keratinocytes and is 
capable of binding the URRs of various HPV types (Bauknecht and Shi, 1998; Wang et al., 
1996). Additionally, HPV E2 directly binds both C/EBPα and C/EBPβ (Bauknecht and Shi, 
1998; Hadaschik et al., 2003). C/EBPβ inhibits both the replication and transcription of 
HPV (Wang et al., 1996). Further studies have revealed that C/EBPβ has three isoforms, I 
(LAP), II (LAP*), and III (LIP), transcribed from a single, intron-less gene with alternative 
start codons for each of the three isoforms (Baer and Johnson, 2000; Descombes and 
Schibler, 1991). LAP activates HPV late transcription by binding the HPV late promoter in a 
differentiation-dependent manner (Gunasekharan et al., 2012). Conversely, LIP has an 
opposite effect on the HPV late transcription. The mechanism for this repression is the 
formation of LIP-LAP dimers which bind to HPV late promoter sequences and prevent 
activation by the LAP transactivation domain. Upon differentiation, HPV positive cells show 
a significant decrease in LIP abundance, increasing the ratio of LAP-LAP homodimers and 
allowing high rates of transcription of late genes (Gunasekharan et al., 2012). Although not 
considered traditional restriction factors, the LIP C/EBPβ isoforms directly restrict the HPV 
life cycle.
4.10 EVERs
Most individuals with the rare genetic disease epidermodysplasia verruciformis have loss of 
function mutations in one of two genes, EVER1/TMC6 or EVER2/TMC8 (Ramoz et al., 
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2002). These individuals have extreme susceptibility to infection by beta HPVs (but not 
other HPVs or other pathogens) and suffer life-long persistent HPV infections of the skin 
(Orth, 2006). While there is evidence that the EVER deficiency might result in defects in the 
adaptive immune system (Lazarczyk et al., 2012), the EVER1 and EVER 2 proteins also 
complex with zinc transporter-1 (ZnT-1) in keratinocytes to control intracellular zinc 
concentration (Lazarczyk et al., 2008). When functional, this complex serves to limit 
intracellular zinc levels in the nucleus, resulting in downregulation of zinc-stimulated 
transcription factors (such as MTF-1) and AP-1 family members such as c-jun. It is 
proposed that in alpha-HPV infected cells, the E5 protein binds to the EVER/ZnT-1 complex 
and blocks this negative modulation (Lazarczyk et al., 2008), whereas beta-HPVs do not 
encode E5 proteins. However, the exact mechanism by which EVER serves to restrict HPV 
infection is unclear. Clearly, more studies are needed to further elucidate the mechanism of 
β-HPV restriction by EVER1/2.
5. Viral Factors that Counteract Host Intrinsic Defenses
A common feature of intrinsic restriction factors is that viruses have evolved mechanisms, or 
encode proteins, that enable them to avoid or antagonize the anti-viral function of restriction 
factors (Yan and Chen, 2012). In fact, viruses often takes advantage of host restriction 
factors to promote latency or persistence (Lieberman, 2016).
One of the earliest defenses that HPV encounters during infection is the ND10 bodies. Many 
DNA viruses localize to these structures during the initial stages of infection and encode 
gene products that directly affect the anti-viral activities of these structures. The HPV minor 
capsid protein L2 is responsible for trafficking the viral genome to the nucleus (Day et al., 
2004). On arrival at ND10, however, L2 reorganizes the ND10 body by recruiting Daxx and 
displacing Sp100 (Becker et al., 2003; Florin et al., 2002; Stepp, 2015). This displacement 
results in the degradation of the Sp100 protein, an event blocked in the presence of the 
proteasome inhibitor, MG132 (Florin et al., 2002). This suggests that L2 not only localizes 
the viral genome to ND10, but also might condition the ND10 environment to be more 
conducive to the establishment of viral genomes.
Papillomaviruses have a very limited coding capacity; thus it is more cost effective to disrupt 
cellular signaling pathways than to directly interact with, and inactivate, host restriction 
factors. The E6 and E7 proteins manipulate many pathways such as cell cycle regulation, the 
DNA damage response and differentiation, and as discussed above there is significant 
overlap with these pathways and those of immune surveillance (Moore and Chang, 2010). 
However, E6 and E7 also directly counteract interferon and NFκB signaling pathways 
(Beglin et al., 2009; Chang and Laimins, 2000; Reiser et al., 2011; Tummers and Burg, 
2015), and E2 can also downmodulate interferon and STING (Sunthamala et al., 2014).
The persistent life cycle of papillomaviruses requires escape from host restriction factors at 
different temporal stages of the infectious cycle, during many diverse cellular processes, and 
in multiple differentiation states of the host cell. It is remarkable that they not only manage 
to evade intrinsic immune surveillance mechanisms but also take advantage of these 
processes to establish long-term infection of the host.
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Highlights
• Papillomavirus transcription and replication can be restricted throughout the 
lifecycle
• Papillomaviruses subvert host restriction factors to complete their life cycle
• Restriction of viral infection can facilitate persistent HPV infection
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Figure 1. HPV genome
Alpha-HPVs have a circular dsDNA genome of approximately 8,000 base pairs. Viral ORFs 
are shown as colored block arrows. Viral early and late promoters are shown as, PE and PL, 
respectively, and polyadenylation sites as pAE and pAL. The origin of replication is shown 
as turquoise bar in the Upstream Regulatory Region (URR).
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Figure 2. Overview of the viral infectious cycle
The virus accesses the basal keratinocytes through a microabrasion. After entering the cell, 
the virus traffics through the endosome. Breakdown of the nuclear envelope during mitosis 
allows the virus to enter the nucleus and viral DNA is observed on mitotic chromosomes, in 
complex with the L2 protein. The L2 genome complex then localizes to ND10 bodies and 
early gene expression occurs. After a short burst of replication, the genome is maintained at 
a low copy number in the dividing cells in the lower levels of the epithelium. As the infected 
keratinocytes differentiate, the genome is amplified to high levels and late genes are 
expressed. The viral genome is assembled in capsids in the superficial layers of the 
epithelium, and viruses are shed from the surface in viral-laden squames. The different steps 
in the viral life cycle are listed below the diagram; host restriction factors can interfere at 
many stages of infection.
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Table 1
HPV Restriction Factors and their viral targets
Restriction
Factor
Viral Target Key Reference
Sp100 Viral transcription (Habiger et al., 2016; Stepp, 2015; Stepp et al., 2013)
miR-145 E1 RNA (Gunasekharan and Laimins, 2013)
p56 E1 Protein (Saikia et al., 2010)
(Terenzi et al., 2008)
IFI16 Early and Late Promoters (Lo Cigno et al., 2015)
C/EBPβ URR, Late Promoter (Gunasekharan et al., 2012)
p53 E2 Protein (Brown et al., 2008; Massimi et al., 1999)
EVERs Viral transcription (Lazarczyk et al., 2008)
APOBEC unknown (Warren et al., 2015b)
FANCD2 unknown (Hoskins et al., 2012)
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